


MEDCAP
INVESTOR
IN LIFE SCIENCE

Company Presentation
2026

We create value in Life Science and contribute to improved quality of life



MedCap Snapshot

Q3 2025

Revenue,
LTM million SEK

1 991

EBITA margin
LTM

17%

Business Areas

Assistive
Tech



MedTech



Specialty
Pharma



Employees & locations

630



Strategy

Buy & Build

*A long-term home for
well run Life Science
companies*


EBITA CAGR
5 years

25%


MedCap | An active investor in Life Science companies

Last Twelve Months, Q3 2025

Sales by Business Area



Sales by Market



Our Model

Life Science

- Sector focus
- Network of expertise
- Knowledge sharing
- Market insight



Entrepreneurship

- Decentralized & local responsibility
- Integrity of acquired brands
- Quick & agile, yet long-term mindset
- Ambitious organic business plans




Group Scale

- Scalable business areas
- Merger & Acquisitions
- Governance – ESG
- Financing



MedCap Business Areas



Our business

Solid markets

Non-cyclical

Demographic drivers

Market niches

Market share potential

Understanding the eco-systems

Payor Prescriber End-user

Healthcare providers Distribution

Regulation Sales & Marketing

Product Development Offering

Active ownership


People & Management

Business objectives

Performance management

Bolt-on acquisitions

How we grow our group



Investment strategy


Scope

- Life Science**
Assistive | MedTech | Pharma
- Europe**
Add-ons globally
- Small / Mid-size Businesses**
Sales <50 mEUR
- Majority Owner**
51-100% Ownership
- Long-term**
Buy & Build | No exit horizon


What we look for



20 years of acquisitions



Sales and EBITA rolling 12 months by quarter



Financial Targets

